Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Abstract: An object of the present invention is to provide a solid pharmaceutical composition which suppresses the characteristic bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has a good storage stability of the-aforementioned compound or a salt thereof. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a carboxylic acid whose solubility in water at 25° C. is 50 g/100 g H2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Abstract: An object of the present invention is to provide a composition for external use having an improved skin permeability of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof. The present invention provides a composition for external use comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, one or more solvents selected from the group consisting of alcohols, sulfoxides and amides, and a permeation enhancer.

Abstract: An object of the present invention is to provide a solid pharmaceutical composition which suppresses the characteristic bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has a good storage stability of the-aforementioned compound or a salt thereof. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a carboxylic acid whose solubility in water at 25° C. is 50 g/100 g H2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.

Abstract: The object of the present invention is to provide a solid pharmaceutical composition in which both the pre-bitter taste and the post-bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof are suppressed. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a compound having at least one hydrocarbon group having 8 to 18 carbon atoms and a sulfo group or a salt thereof.

Abstract: Provided are an injection preparation which includes: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent A which is selected from the group consisting of cysteine and a salt thereof, and of which the content is 0.001 mass % to 0.1 mass % with respect to the total mass of the aqueous composition, thioglycerol of which the content is 0.001 mass % to 0.1 mass % with respect to the total mass of the aqueous composition, and an aqueous solvent of which the content is greater than or equal to 50 mass % with respect to the total mass of the aqueous composition, and a container which seals the aqueous composition, in which the concentration of oxygen in gas within the container which seals the aqueous composition is less than or equal to 2.0 volume %, and a method for producing the injection preparation.

Abstract: Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation.

Abstract: Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation.

Abstract: An aqueous ophthalmic composition includes a carbonic anhydrase inhibitor; at least one cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate and carboxymethylethyl cellulose; and water.

Abstract: An orally disintegrating tablet including: fine granules, each fine granule having, at its center, an active pharmaceutical ingredient-containing core that includes butylscopolamine bromide and water-insoluble particles, and having an intermediate layer that includes water-insoluble particles and coats the active pharmaceutical ingredient-containing core, and a bitterness-masking layer that includes talc and at least one water-insoluble polymer, in sequence from the active pharmaceutical ingredient-containing core side; and an excipient component positioned on the outside of the fine granules, and a method for producing the same.

Abstract: Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation.

Abstract: An emulsion composition includes a compound having a diaminopyrimidine skeleton, at least one fatty acid component selected from the group consisting of a fatty acid having a total carbon number of 14 or more and a salt thereof, and an aqueous medium in an amount of 50% by mass or more with respect to the mass of the emulsion composition. The total amount of monohydric alcohol having a total carbon number of 3 or less and dihydric alcohol having a total carbon number of 3 or less is less than 10% by mass with respect to the mass of the emulsion composition. The emulsion composition has a pH of 6.5 or more.

Abstract: Provided are a propofol-containing oil-in-water emulsion composition having high stability even in a case in which the emulsion composition is charged into a plastic container; and a method for producing the same. Provided is a propofol-containing oil-in-water emulsion composition including at least one selected from the group consisting of trishydroxymethylaminomethane, phosphoric acid, and triethanolamine; propofol; an oily component; an emulsifier; and water, in which a dissolved oxygen concentration is 5 mg/L or less and an average emulsion particle size is 180 nm or less.

Abstract: An emulsion composition includes a compound having a diaminopyrimidine skeleton, at least one fatty acid component selected from the group consisting of a fatty acid having a total carbon number of 14 or more and a salt thereof, and an aqueous medium in an amount of 50% by mass or more with respect to the mass of the emulsion composition. The total amount of monohydric alcohol having a total carbon number of 3 or less and dihydric alcohol having a total carbon number of 3 or less is less than 10% by mass with respect to the mass of the emulsion composition. The emulsion composition has a pH of 6.5 or more.

Abstract: An aqueous ophthalmic composition includes a carbonic anhydrase inhibitor; at least one cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate and carboxymethylethyl cellulose; and water.

Abstract: A method of producing an aqueous ophthalmic composition includes wet grinding a mixture that includes a carbonic anhydrase inhibitor, a cellulose derivative, and water, in which a 2%-by-mass aqueous solution of the cellulose derivative has a viscosity of 60 mPa·s or less at 20° C. An aqueous ophthalmic composition includes a carbonic anhydrase inhibitor, a cellulose derivative, and water, in which an absorbance of the aqueous ophthalmic composition at a wavelength of 600 nm and an optical path length of 1 mm is 1.1 or less and a 2%-by-mass aqueous solution of the cellulose derivative has a viscosity of 60 mPa·s or less at 20° C.

Abstract: Provided are an injection preparation which includes: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent A which is selected from the group consisting of cysteine and a salt thereof, and of which the content is 0.001 mass % to 0.1 mass % with respect to the total mass of the aqueous composition, thioglycerol of which the content is 0.001 mass % to 0.1 mass % with respect to the total mass of the aqueous composition, and an aqueous solvent of which the content is greater than or equal to 50 mass % with respect to the total mass of the aqueous composition, and a container which seals the aqueous composition, in which the concentration of oxygen in gas within the container which seals the aqueous composition is less than or equal to 2.0 volume %, and a method for producing the injection preparation.

Abstract: Provided are an injection preparation which include: an aqueous composition containing pemetrexed or a salt thereof, at least one antioxidant agent which is selected from the group consisting of ascorbic acid, an ascorbic acid derivative, and salts thereof, and the content of which is 0.0001 mass % to 0.5 mass % with respect to the total mass of the aqueous composition in terms of ascorbic acid, and an aqueous solvent of greater than or equal to 50 mass % with respect to the total mass of the aqueous composition; and a container which encloses the aqueous composition, in which the concentration of oxygen in gas within the container which encloses the aqueous composition is less than or equal to 0.2 volume %, and a method for producing the injection preparation.

Abstract: An emulsion composition includes a compound having a diaminopyrimidine skeleton, at least one fatty acid component selected from the group consisting of a fatty acid having a total carbon number of 14 or more and a salt thereof, and an aqueous medium in an amount of 50% by mass or more with respect to the mass of the emulsion composition. The total amount of monohydric alcohol having a total carbon number of 3 or less and dihydric alcohol having a total carbon number of 3 or less is less than 10% by mass with respect to the mass of the emulsion composition. The emulsion composition has a pH of 6.5 or more.